Dilution of Verapamil During Intraarterial Administration
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study will be a randomized, single-blind, prospective trial designed to evaluate the
efficacy and safety of intra-arterial (IA) Verapamil diluted with normal saline compared to
undiluted IA Nicardipine during transradial access (TRA) for percutaneous coronary
angiography. Patients who are 18 years or older and undergoing non-emergent percutaneous
coronary angiography via TRA will be included. Patients who are non-English speaking,
pregnant, or intubated will be excluded. Patients will be randomized to one of the two
following groups:
1. Group 1 will receive IA Verapamil 5 mg (2mL) diluted with 8 mL of normal saline
2. Group 2 will receive IA Nicardipine 400 mcg (undiluted, 8 mL)
The investigators will document the patient's level of discomfort on the Visual Analogue
Scale 30 seconds before and after administration of IA Verapamil/Nicardipine. The
investigators will also document the presence of radial artery spasms.